Impaired CD8+ T-cell reactivity against viral antigens in cancer patients with solid tumors

Infection

Volumn 32, Issue 5, 2004, Pages 287-292

  Trojan, A ^a   Giger, R ^a   Rist, N ^a   Speck, R F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; MESSENGER RNA; VACCINIA VACCINE; VIRUS ANTIGEN; VIRUS PROTEIN;

ADULT; AGED; ANTIGEN RECOGNITION; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; INFLUENZA VIRUS; KIDNEY CARCINOMA; LIPOSARCOMA; LUNG CANCER; MALE; OROPHARYNX CANCER; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; SOLID TUMOR; VACCINIA VIRUS;

ADULT; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; INFLUENZA A VIRUS; INTERFERON TYPE II; MALE; MIDDLE AGED; NEOPLASMS; RNA, MESSENGER; VACCINIA VIRUS;

EID: 4844227174     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-004-3140-y     Document Type: Article

References (37)

1. Ennis FA, Cruz J, Demkowicz WE Jr, Rothman AL, McClain, DJ: Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T cells after small pox vaccination. J Infect Dis 2002; 185: 1657-1659.
2. Gotch F, Rothbard J, Howland K, Townsend A, McMichael A: Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature 1987; 326: 881-882.
3. Kammula, US, Marincola FM, Rosenberg SA: Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst 2000; 92: 1336-1344.
4. Nielsen MB, Monsurro V, Migueles SA, Wang E, Perez-Diez A, Lee KH, et al.: Status of activation of circulating vaccine-elicited CD8+ T-cells. J Immunol 2000; 165: 2287-2296.
5. Trojan A, Schultze JL, Witzens M, Vonderheide RH, Ladetto M, Donovan JW et al.: Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 2000; 6: 667-672.
6. Drexler I, Staib C, Kastenmuller W, Stevanovic S, Schmidt B, Lemonnier FA, et al.: Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T-cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci USA 2003; 100: 217-222.
7. Jameson J, Cruz J, Ennis FA: Human cytotoxic T-lymphocyte repertoire to influenza A viruses: J Virol 1998; 72: 8682-8689.
8. Demkowicz WE Jr, Littaua RA, Wang J, Ennis FA: Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J Virol 1996; 70: 2627-2631.
9. Frey SE, Newman FK, Cruz J, Shelton WB, Tennant JM, Polach T, et al.: Dose-related effects of smallpox vaccine. N Engl J Med 2002; 346: 1275-1280.
10. Lehner PJ, Wang EC, Moss PA, Williams S, Platt K, Friedman SM, et al.: Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T-cells bearing the V beta 17 gene segment. J Exp Med 1995; 181: 79-91.
11. Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H, et al.: Mage-3 and influenza-matrix peptide-specific cytotoxic T-cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol 2000; 165: 3492-3496.
12. Birmingham K, Kenyon G: Smallpox vaccine development quickened. Nat Med 2001; 7: 1167.
13. Redfield, RR, Wright DC, James WD, Jones TS, Brown C, Burke DS: Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987; 316: 673-676.
14. Drexler I, Antunes E, Schmitz M, Wolfel T, Huber C, Erfle V, et al.: Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. Cancer Res 1999; 59: 4955-4963.
15. Maecker B, Anderson KS, Bergwelt-Baildon MS, Weller E, Vonderheide RH, Richardson PG, et al.: Viral antigen-specific CD8(+) T-cell responses are impaired in multiple myeloma. Br J Haematol 2003; 121: 842-848.
16. Mariani S, Coscia M, Even J, Peola S, Foglietta M, Boccadoro M, et al.: Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. Br J Haematol 2001; 113: 1051-1059.
17. De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, Lieto E, et al: Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 2000; 117: 365-373.
18. Sharma S, Stolina M, Lin Y, Gardner B, Miller P. W, Kronenberg M, et al.: T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 1999; 163: 5020-5028.
19. Carreno BM, Koenig S, Coligan JE, Biddison WE: The peptide binding specificity of HLA class I molecules is largely allele-specific and non-overlapping. Mol Immunol 1992; 29: 1131-1140.
20. Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA, et al.: Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol 1999; 163: 6867-6875.
21. Sauma SY, Gammon MC, Bednarek MA, Cunningham B, Biddison WE, Hermes JD, et al.: Recognition by HLA-A2-restricted cytotoxic T lymphocytes of endogenously generated and exogenously provided synthetic peptide analogues of the influenza A virus matrix protein. Hum Immunol 1993; 37: 252-258.
22. Scheibenbogen C, Lee KH, Mayer S, Stevanovic S, Moebius U, Herr W, et al.: A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res 1997; 3: 221-226.
23. Trojan A, Urosevic M, Hummerjohann J, Giger R, Schanz U, Stahel RA: Immune reactivity against a novel HLA-A3-restricted influenza virus peptide identified by predictive algorithms and interferon-gamma quantitative PCR. J Immunother 2003; 26: 41-46.
24. Pittet MJ, Zippelius A, Speiser DE, Assenmacher M, Guillaume P, et al.: Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol 2001; 166: 7634-7640.
25. Trojan A, Urosevic M, Dummer R, Nestle FO, Stahel RA: Real-time polymerase chain reaction monitoring of epithelial cell adhesion molecule-induced T cell stimulation in patients with lung cancer and healthy individuals using lightcycler technology. J Immunother 2002; 25: 264-268.
26. Provenzano M, Mocellin S, Bonginelli P, Nagorsen D, Known SW, Stroneck DF: Ex vivo screening for immunodominant viral epitopes by quantitative real time polymerase chain reaction (qRT-PCR). J Transl Med 2003; 1: 12-18.
27. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, et al.: Duration of antiviral immunity after smallpox vaccination. Nat Med 2003; 9: 1131-1137.
28. Dunbar PR, Ogg GS, Chen J, Rust N, van der Bruggen P, Cerundolo V: Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr Biol 1998; 8: 413-416.
29. Grayson JM, Murali-Krishna K, Altman JD, Ahmed R: Gene expression in antigen-specific CD8+ T cells during viral infection. J Immunol 2001; 166: 795-799.
30. Lawson TM, Man S, Williams S, Boon AC, Zambon M, Borysiewicz LK: Influenza A antigen exposure selects dominant Vbeta17+ TCR in human CD8+ cytotoxic T-cell responses. Int Immunol 2001; 13: 1373-1381.
31. Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS, et al.: Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci USA 2003; 100: 9458-9463.
32. Erickson AL, Walker CM: Class I major histocompatibility complex-restricted cytotoxic T-cell responses to vaccinia virus in humans. J Gen Virol 1993; 74: 751-754.
33. Kay, NE, Leong TL, Bone N, Vesole DH, Greipp PR, Van Ness B, et al.: Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood 2001; 98: 23-28.
34. Massaia M, Borrione P, Attisano C, Barral P, Beggiato E, Montacchini L, et al.: Dysregulated fas and Bcl-2 expression leading to enhanced apoptosis in T-cells of multiple myeloma patients. Blood 1995; 85: 3679-3687.
35. Dhodapkar M. V, Geller M. D, Chang D. H, Shimizu K, Fujii S, Dhodapkar K. M, et al.: A reversible defect in natural killer T-cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 2003; 197: 1667-1676.
36. Terajima, M. Cruz, J. Raines, G. Kilpatrick, E. D. Kennedy, J. S, et al.: Ouantitation of CD8+ T-cell responses to newly identified HLA-A*0201- restricted T-cell epitopes conserved among vaccinia and variola (smallpox) viruses. J Exp Med 2003; 197: 927-932.
37. Scheibenbogen C, Romero P, Rivoltini L, Herr W, Schmittel A, Cerottini J. C, et al.: Ouantitation of antigen-reactive T-cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods 2000; 244: 81-89.